Latest news with #SLE
Hindustan Times
a day ago
- Health
- Hindustan Times
Urologist shares why young Indians are getting kidney diseases without realising it
Did you know actor Rana Daggubati received a kidney transplant a few years ago? While kidney disease doesn't typically get as much attention as the other health conditions like heart disease, in an interview with HT Lifestyle, Dr Santosh Gawali, senior consultant urologist and transplant surgeon at Jaslok Hospital and Research Centre, Mumbai, shared that young people are increasingly being diagnosed with kidney ailments. Also read | Miracles of kidney transplant: Benefits, procedure, everything to know for those suffering from end-stage renal disease It's important to point out that chronic kidney disease is a broad term for a range of illnesses. Dr Gawali explains, 'Kidney ailments in young age groups can be broadly classified into congenital/ inherited causes and acquired causes. Inherited causes include early-onset hypertension, Type 1 diabetes occurring in young age groups, leading to kidney failure in the long run. The list of rare inherited disorders with renal involvement is rapidly growing due to various factors like increasing recognition by genetic testing/imaging, increased exposure to environmental toxins, maternal diet, lifestyle changes, and increasing maternal age.' He adds, 'Autoimmune Diseases such as IgA nephropathy and lupus nephritis ( SLE ) may trigger kidney inflammation, which in turn can cause chronic kidney disease (CKD). Family history also plays a major role in diseases like Polycystic Kidney Disease (PKD). CKD may occur as a result of renal scarring due to recurrent urinary tract infections. Some of them may have congenital Vesicoureteric reflux disease.' According to him, acquired causes include increasing rates of obesity rates among young adults, in their 20s, 'due to modern lifestyle changes including increased exposure to fast food, high screen time, and higher stress levels'. Dr Gawali says, 'Increasing rates of smoking in young age causes early onset of hypertension and a high risk of renal cancer. Recreational drugs have been associated with irreversible kidney injury.' He adds, 'There is an increased tendency of the younger age groups for consumption of heavy protein supplements, animal protein, steroids, with reduced amounts of vegetable protein and strenous exercises, dehydration, which, along with reduced fluid intake, leads to renal damage over long run. Recurrent urinary tract infections and stone disease too cause renal damage in long run.' Dr Gawali suggests avoiding excessive protein supplements and pain killers and staying hydrated. He says, 'Diet involving increased vegetable protein intake, reduced animal protein and supplements with adequate fluid intake. Regular physical activity is beneficial for overall health Maintaining a healthy body weight can help reduce stress on the kidneys and improve overall health. Cessation of recreational drug use/ smoking/ alcohol. Avoiding excessive protein supplements, pain killers and proper water intake is also important to protect the kidneys.' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Yahoo
3 days ago
- Business
- Yahoo
Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases
Fate Therapeutics, Inc. (NASDAQ:FATE) announced today that it will present groundbreaking clinical data from its Phase 1 trial of FT819, an off-the-shelf, iPSC-derived CAR T-cell therapy, at the upcoming EULAR 2025 Congress in Barcelona. FT819 targets CD19 and is being evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE) without the use of fludarabine conditioning, a significant shift from traditional CAR T-cell approaches. The oral presentation, scheduled for June 11, will highlight FT819's safety and efficacy in lupus patients treated with either a fludarabine-free regimen or maintenance therapy without conditioning. This approach could eliminate the need for toxic chemotherapy, potentially enabling safer, more accessible outpatient treatment for autoimmune diseases. A biotechnologist in a lab overlooking a microscope, examining a sample of substances to test for therapeutic properties. Fate Therapeutics, Inc. (NASDAQ:FATE) will also showcase preclinical advances in its iPSC-derived CAR T and CAR-NK cell platforms, including Sword and Shield technology and multi-antigen targeting, aimed at broadening autoimmune therapy applications. The company's proprietary iPSC platform allows for scalable, off-the-shelf cell therapies, positioning Fate Therapeutics, Inc. (NASDAQ:FATE) as a leader in next-generation immunotherapies for autoimmune conditions. While we acknowledge the potential of AMZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMZN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced that clinical and preclinical data from the Company's off-the-shelf cell therapy product platform will be featured at the European Alliance of Associations for Rheumatology European Congress of Rheumatology (EULAR 2025), being held in Barcelona, Spain on June 11-14, 2025. The Company has been selected to provide an oral presentation featuring clinical data from its ongoing Phase 1 clinical trial of FT819, its off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate, in patients with moderate-to-severe systemic lupus erythematosus (SLE) (NCT06308978). The Phase 1 study is designed to evaluate the safety and activity of FT819 in patients receiving either a fludarabine (flu)-free conditioning regimen or maintenance therapy without conditioning. In addition, the Company will highlight preclinical and translational data from its off-the-shelf, iPSC-derived, CAR T-cell and CAR-NK cell product platform across multiple autoimmune indications, including the use of Sword and Shield technology and multi-antigen targeting to circumvent the need for conditioning chemotherapy, enhance therapeutic outcomes, and maximize patient access by enabling outpatient treatment. Accepted abstracts are available on the EULAR 2025 website. Presentation details are as follows: Oral Presentation Treatment of Refractory Systemic Lupus Erythematosus with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy Session: Cell Therapies – CAR-T and BeyondPresentation Date / Time: Wednesday, June 11, 2025 / 3:20 PM CEST Poster Presentations Next-Generation Off-the-Shelf CAR T Cells: A Novel Platform to Enable Comprehensive Elimination of Aberrant Effector Cells for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy Session: Basic and Clinical Poster Tours: CAR T-cells and other emerging Therapies Presentation Date / Time: Thursday, June 12, 2025 / 9:54am CEST Next Generation CAR-NK cell Therapy Leverages Alloimmune Defense Technology to Persist Without Conditioning Chemotherapy for the Treatment of Autoimmune Disease Session: Poster View VIIIPresentation Date / Time: Saturday, June 14, 2025 / 10:15-11:45am CEST About Fate Therapeutics' iPSC Product PlatformHuman induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be administered in combination with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, the availability of data from the Company's clinical trials and the Company's plans to provide updates on its clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, and the Company's clinical and product development strategy. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company's product candidates or in the initiation and conduct of, or enrollment and continued participation of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact:Christina TartagliaPrecision
Yahoo
3 days ago
- Business
- Yahoo
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced that clinical and preclinical data from the Company's off-the-shelf cell therapy product platform will be featured at the European Alliance of Associations for Rheumatology European Congress of Rheumatology (EULAR 2025), being held in Barcelona, Spain on June 11-14, 2025. The Company has been selected to provide an oral presentation featuring clinical data from its ongoing Phase 1 clinical trial of FT819, its off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate, in patients with moderate-to-severe systemic lupus erythematosus (SLE) (NCT06308978). The Phase 1 study is designed to evaluate the safety and activity of FT819 in patients receiving either a fludarabine (flu)-free conditioning regimen or maintenance therapy without conditioning. In addition, the Company will highlight preclinical and translational data from its off-the-shelf, iPSC-derived, CAR T-cell and CAR-NK cell product platform across multiple autoimmune indications, including the use of Sword and Shield technology and multi-antigen targeting to circumvent the need for conditioning chemotherapy, enhance therapeutic outcomes, and maximize patient access by enabling outpatient treatment. Accepted abstracts are available on the EULAR 2025 website. Presentation details are as follows: Oral Presentation Treatment of Refractory Systemic Lupus Erythematosus with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy Session: Cell Therapies – CAR-T and BeyondPresentation Date / Time: Wednesday, June 11, 2025 / 3:20 PM CEST Poster Presentations Next-Generation Off-the-Shelf CAR T Cells: A Novel Platform to Enable Comprehensive Elimination of Aberrant Effector Cells for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy Session: Basic and Clinical Poster Tours: CAR T-cells and other emerging Therapies Presentation Date / Time: Thursday, June 12, 2025 / 9:54am CEST Next Generation CAR-NK cell Therapy Leverages Alloimmune Defense Technology to Persist Without Conditioning Chemotherapy for the Treatment of Autoimmune Disease Session: Poster View VIIIPresentation Date / Time: Saturday, June 14, 2025 / 10:15-11:45am CEST About Fate Therapeutics' iPSC Product PlatformHuman induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be administered in combination with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with patient- and donor-sourced cell therapies. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, the availability of data from the Company's clinical trials and the Company's plans to provide updates on its clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, and the Company's clinical and product development strategy. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company's product candidates or in the initiation and conduct of, or enrollment and continued participation of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact:Christina TartagliaPrecision in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
4 days ago
- Health
- Medscape
Long-Term Anifrolumab Use Improves Quality of Life in Lupus
Patients with moderate to severe active systemic lupus erythematosus (SLE) who continued anifrolumab treatment over 4 years showed sustained improvements in health status and quality of life, along with improvements in health utilities and employment measures. METHODOLOGY: Researchers conducted an extension trial (TULIP-LTE) to assess the long-term effects of anifrolumab treatment on patient-reported outcomes in SLE at baseline through week 208. They included 369 patients with moderate to severe SLE who were randomly assigned to receive either 300 mg anifrolumab (n = 257; mean age, 43.4 years; 92% women) or placebo (n = 112; mean age, 41.4 years; 92% women) every 4 weeks. These patients had completed the 1-year TULIP-1 and TULIP-2 trials and maintained the same treatment in the long-term extension study. Exploratory endpoints were changes in patient-reported outcomes related to health status and health-related quality of life. TAKEAWAY: At week 208, the anifrolumab group had numerically higher Short Form-36 version 2 acute recall scores for mental health and bodily pain domains than the placebo group (least squares mean [LSM] difference, 3.7; 95% CI, −1.2 to 8.6 and 5.9; 95% CI, −0.7 to 12.5, respectively). The Short Form-6 Dimension scores showed numerically greater improvements in the anifrolumab group than in the placebo group, with differences evident from week 24 (LSM difference, 0.013; 95% CI, −0.007 to 0.032) and sustained through week 208 (LSM difference, 0.016; 95% CI, −0.010 to 0.042). Similarly, Patient Global Assessment and EuroQoL 5 Dimensions–derived Single Summary Utility Index scores showed numerically greater improvements in the anifrolumab group than in the placebo group at week 208. At week 208, the proportion of patients in paid employment remained stable in both the anifrolumab and placebo groups (45% vs 44%), with both groups showing similar reductions in the number of work hours missed in the preceding week. IN PRACTICE: 'These findings highlight the importance of including patient-reported outcomes as single, composite indices (eg, SF-6D) in clinical trials to allow comprehensive assessment of meaningful benefit for patients,' the authors wrote. SOURCE: This study was led by Vibeke Strand, MD, Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, and was published online on May 2, 2025, in The Lancet Rheumatology . LIMITATIONS: The exploratory and post hoc nature of the analysis may have limited the interpretation of the results, as the trials were not powered for the exploratory endpoints examined. Patients with active, severe lupus nephritis or severe neuropsychiatric SLE were not included. Additionally, the study did not include any individuals with lived experience of SLE at any stage of its design, conduct, or reporting. DISCLOSURES: This study was funded by AstraZeneca. One author reported receiving honorarium and consulting fees from various pharmaceutical companies and other sources, including AstraZeneca. Another author reported receiving consulting fees from AstraZeneca. A few authors reported being current or former employees or holding stocks of AstraZeneca or having other ties with a biotechnology company.
